| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
| Targets |
Purine nucleoside metabolism pathways; DNA synthesis. As a purine nucleoside analog, 8-Bromo-2'-deoxyadenosine is incorporated into DNA, disrupting nucleic acid synthesis. The bromine atom at position 8 may affect DNA structure and stability. The compound targets rapidly dividing cells, particularly lymphoid malignancies.
|
|---|---|
| ln Vitro |
8-Bromo-2'-deoxyadenosine demonstrates activity as a purine nucleoside analog in cellular assays. It exerts anticancer effects primarily through the inhibition of DNA synthesis and the induction of apoptosis. It has demonstrated broad antitumor activity, particularly against indolent lymphoid malignancies. Detailed IC50 values have not been disclosed.
|
| ln Vivo |
8-Bromo-2'-deoxyadenosine has potential applications in cancer research due to its ability to interfere with DNA synthesis in rapidly dividing cells, leading to cell death or growth inhibition. It is used to measure the kinetics of oxidative DNA damage and to study glycosidic bond cleavage reactions. In vivo studies would be needed to evaluate its therapeutic potential.
|
| Enzyme Assay |
In vitro assays for purine nucleoside analogs typically involve measuring inhibition of DNA synthesis using radiolabeled thymidine incorporation. For DNA damage studies, the compound is used to measure oxidative DNA damage kinetics and glycosidic bond cleavage reactions. Cell viability is assessed by MTT or CellTiter-Glo assays.
|
| Cell Assay |
Cells (e.g., lymphoid malignancy cell lines or other cancer cell lines) are cultured and treated with 8-Bromo-2'-deoxyadenosine at concentrations typically ranging from 0.1–100 μM for 24–72 hours. DNA synthesis inhibition is measured by BrdU incorporation. Cell viability is assessed by standard assays. DNA damage is evaluated by comet assay or γ-H2AX staining.
|
| Animal Protocol |
In vivo animal studies for 8-Bromo-2'-deoxyadenosine have not been reported. The compound is primarily used as a research tool for DNA damage and nucleoside analog studies. Future studies in xenograft models would be needed to evaluate in vivo efficacy.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 8-Bromo-2'-deoxyadenosine have not been published. The compound has a molecular weight of 330.14 and formula C10H12BrN5O3. The bromine atom may affect metabolic stability and tissue distribution. In vivo PK parameters have not been characterized.
|
| Toxicity/Toxicokinetics |
Toxicology data for 8-Bromo-2'-deoxyadenosine have not been published. The compound is for research use only and not approved for human therapeutic applications. No systematic toxicological evaluation has been performed. Standard safety precautions for handling brominated compounds should be observed.
|
| References | |
| Additional Infomation |
8-Bromo-2'-deoxyadenosine (CAS: 14985-44-5, molecular formula C10H12BrN5O3, molecular weight 330.14) is a brominated purine nucleoside analog. It exerts anticancer effects through inhibition of DNA synthesis and induction of apoptosis. It is used to study oxidative DNA damage and glycosidic bond cleavage. It is not in clinical trials and has no regulatory approval.
|
| Molecular Formula |
C10H12BRN5O3
|
|---|---|
| Molecular Weight |
330.14
|
| Exact Mass |
329.012
|
| CAS # |
14985-44-5
|
| PubChem CID |
96547
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
2.3g/cm3
|
| Boiling Point |
671ºC at 760mmHg
|
| Flash Point |
359.6ºC
|
| Vapour Pressure |
6.41E-19mmHg at 25°C
|
| Index of Refraction |
1.898
|
| LogP |
0.392
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
19
|
| Complexity |
338
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C1[C@@H]([C@H](O[C@H]1N2C3=NC=NC(=C3N=C2Br)N)CO)O
|
| InChi Key |
NJBIVXMQFIQOGE-KVQBGUIXSA-N
|
| InChi Code |
InChI=1S/C10H12BrN5O3/c11-10-15-7-8(12)13-3-14-9(7)16(10)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,13,14)/t4-,5+,6+/m0/s1
|
| Chemical Name |
(2R,3S,5R)-5-(6-amino-8-bromopurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0290 mL | 15.1451 mL | 30.2902 mL | |
| 5 mM | 0.6058 mL | 3.0290 mL | 6.0580 mL | |
| 10 mM | 0.3029 mL | 1.5145 mL | 3.0290 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
